Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment
Aichi Cancer Center and Fujitsu today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants. With current cancer genomic medicine in Japan, treatment plans are considered based on the patients’ unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells. Specialists for cancer drug treatment thus rely on their own experience, knowledge, and medical literature to study treatment strategies in order to find the best possible medication for the patients’ individual conditions.
Test data of effective medical treatment of different cancer types and genomic information in external databases, which are sorted and managed based on different keywords and rules, remain difficult to use. Aichi Cancer Center and Fujitsu anticipate that the new solution will contribute to a significant reduction in the time required for physicians to estimate the effectiveness of drugs in a clinical setting, as well as to conduct research about data that can be used as evidence for their estimations. The effectiveness of the new solution has been verified in clinical trials by physicians at Aichi Cancer Center.